Ask about this productRelated genes to: STYK1 antibody
- Gene:
- STYK1 NIH gene
- Name:
- serine/threonine/tyrosine kinase 1
- Previous symbol:
- -
- Synonyms:
- SuRTK106, DKFZp761P1010, NOK
- Chromosome:
- 12p13.2
- Locus Type:
- gene with protein product
- Date approved:
- 2005-01-21
- Date modifiied:
- 2016-07-08
Related products to: STYK1 antibody
Related articles to: STYK1 antibody
- Vascular invasion (VI) is an essential step in the progression of breast cancer (BC) and is a key factor behind morbidity and mortality. In a previous work using gene expression profiling, upregulation of was one of the genetic changes that was found associated with VI. The aims of the following study were to assess (1) level and pattern of STYK1 expression in BC tissues and (2) its association with clinicopathological features and with patient outcome. Histopathological, clinical data and 10‒year survival data for 220 primary breast carcinoma was retrieved. From each specimen, one representative formalin-fixed paraffin-embedded tissue section was stained by immunohistochemistry (IHC) with STYK1 antibodies. IHC score was calculated and correlated with clinicopathological features of tumors. Higher STYK1 expression was detected in invasive BC compared with normal and non-invasive tumors, and was significantly associated with the presence of vascular invasion (, lymph node metastasis ( estrogen receptor positivity , non‒triple negative phenotype ( and occurrence of locoregional recurrence No association was detected with other tumor features such as tumor size, grade, development of distant metastasis or overall survival. STYK1 is expressed at a higher level in invasive BC compared with non-cancerous tissues. This high expression is significantly associated with presence of VI, LN metastasis and occurrence of recurrence. These findings suggest that STYK1 could be a possible molecular target for breast carcinoma. Targeted therapy that can inhibit STYK1 kinase can be a possible approach for the development of novel therapies in breast carcinoma. - Source: PubMed
Publication date: 2026/02/08
Mohammed RababIsmaeel AminaAlshaikh SafaMubarak AalaaSabt SajedahSelvam Samvel - Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy with limited treatment options. Immunotherapy, though effective in various tumors, has limited efficacy in PDAC due to immune tolerance. Thus, identifying new targets to enhance immunotherapy response is crucial. - Source: PubMed
Publication date: 2025/09/19
Wang XiaoZhang YueqinLi AnanZhou ChuanzanXu SenGu ZongtingWang WeiNan PengTao Ran - The Wnt/β-catenin pathway is strongly relevant to pancreatic cancer progression, poor prognostic outcomes, and elevated cancer-related mortality. However, the mechanism underlying continuously activated Wnt/β-catenin signaling in pancreatic cancer, a context in which adenomatous polyposis coli (APC) mutations are rarely observed, remains poorly understood. In this study, we investigated the role of STYK1 in regulating canonical Wnt/β-catenin signaling and pancreatic cancer tumorigenesis using the LSL-Kras; Trp53; Pdx1 mouse model. Our findings demonstrate that STYK1 directly binds to β-catenin and GSK3β, inhibiting GSK3β activity by increasing the level of its kinase-inactive form, which is phosphorylated at S9, and promoting its sequestration into MVBs. We further showed that STYK1-mediated GSK3β sequestration is impaired by autophagy inhibitors or in ATG7 knockout cells, linking this process to autophagic regulation. Structural analysis identified conserved tyrosine-based (Y191QRL194) and dileucine-based (GDLL203-204) sorting motifs in STYK1, which facilitate clathrin/AP2-dependent internalization essential for GSK3β sequestration. The phosphorylation of STYK1 at Y191 by BLK kinase enhances its interaction with AP2, thereby accelerating GSK3β sequestration and subsequent Wnt/β-catenin pathway activation. Notably, inhibitory peptides targeting either the STYK1-β-catenin or the STYK1-GSK3β interface significantly suppressed pancreatic cancer development in vitro and in vivo, underscoring their therapeutic potential. Collectively, these results elucidate a novel STYK1-driven mechanism for Wnt/β-catenin activation in APC-independent pancreatic cancer and provide preclinical evidence for targeting STYK1-mediated signaling as a therapeutic strategy. - Source: PubMed
Publication date: 2025/06/30
Zhou CefanDong XueyingLi ShiXi YueLiu YuanQian XuehongSong ZiyanZhou LiZhang RuiLyu HaoXiao ShuaiGuo DongZhang QiLiu WeiyongXiong YanWang ZhentianYan ChaojunZhang ZijianZhu HaichuanChen Xing-ZhenSong ZhiyinTang Jingfeng - Prostate cancer (PCa) is a prevalent malignant tumor in men worldwide. Kinases play a key role in the development of multiple tumors. Nevertheless, the role of kinases in PCa remains largely unclear. - Source: PubMed
Publication date: 2025/02/17
Huang YaqiangZhu HaiyingLiang ZhenguoWei WeiyangYang HaoWang QiHuang HongxingHe HuichanMo RujunYe JianhengDai QishanZhong WeideLiang Yingke - This study employs bibliometric analysis to track evolution and identify trends of key topics in ferroptosis within the context of lung cancer. By identifying emerging research areas, our aim is to provide valuable insights and directions for researchers in this field. - Source: PubMed
Publication date: 2025/01/29
Yao FeifeiGuo FengSun ChuanzhongWang ErdongWang HangLi Na